logo

ARMP

Armata PharmaceuticalsยทAMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --

ARMP Profile

Armata Pharmaceuticals, Inc.

A clinical-stage biopharmaceutical company focusing on targeted phage therapy for antibiotic-resistant infections

Biological Technology
--
08/21/2015
American Stock Exchange
60
12-31
Common stock
5005 McConnell Avenue, Los Angeles, CA 90066
--
Armata Pharmaceuticals, Inc., was established under Washington state law in March 1989 as a wholly-owned subsidiary of Immunex Corporation and began operations in 1992 as an independent targeted genetics company. The company is a clinical-stage biotechnology company focused on developing pathogen-specific phage therapies for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using proprietary phage-based technologies.